141 related articles for article (PubMed ID: 34255923)
1. Serum tumour M2-pyruvate kinase as a biomarker for diagnosis and prognosis of early-stage non-small cell lung cancer.
Xu C; Liu W; Li L; Wang Y; Yuan Q
J Cell Mol Med; 2021 Aug; 25(15):7335-7341. PubMed ID: 34255923
[TBL] [Abstract][Full Text] [Related]
2. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
Ugurel S; Bell N; Sucker A; Zimpfer A; Rittgen W; Schadendorf D
Int J Cancer; 2005 Dec; 117(5):825-30. PubMed ID: 15957165
[TBL] [Abstract][Full Text] [Related]
3. Enzyme Kinetic Assay to Measure the Activity of Tumor M2 Pyruvate Kinase in Breast Cancer Patients.
Guan M; Tong Y; Liu X; Dong D; Zhou Y
Ann Clin Lab Sci; 2017 Nov; 47(6):676-686. PubMed ID: 29263041
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
Li L; Zhang Q; Wang Y; Xu C
J Clin Lab Anal; 2023 Apr; 37(7):e24865. PubMed ID: 37088873
[TBL] [Abstract][Full Text] [Related]
6. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
Ervens J; Fuchs H; Niemann VT; Hoffmeister B
J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
[TBL] [Abstract][Full Text] [Related]
7. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
8. Pyruvate kinase type tumor M2 in urological malignancies.
Hegele A; Varga Z; Kosche B; Stief T; Heidenreich A; Hofmann R
Urol Int; 2003; 70(1):55-8. PubMed ID: 12566817
[TBL] [Abstract][Full Text] [Related]
9. Plasma TuM2-PK correlates with tumor size, CRP and CA 15-3 in metastatic breast carcinomas; short versus long term follow up study of the Egyptian breast cancer patients.
El-Abd E; El-Sheikh M; Zaky S; Fayed W; El-Zoghby S
Cancer Biomark; 2017 Aug; 20(2):123-133. PubMed ID: 28869444
[TBL] [Abstract][Full Text] [Related]
10. Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker?
Varga Z; Hegele A; Stief T; Heidenreich A; Hofmann R
Urol Res; 2002 May; 30(2):122-5. PubMed ID: 12086017
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum and pleural levels tumor M2-pyruvate kinase in lung cancer patients with pleural effusion.
Zhang T; Liu W; Li L; Jue Z; Xu C
BMC Pulm Med; 2022 Aug; 22(1):307. PubMed ID: 35948914
[TBL] [Abstract][Full Text] [Related]
12. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.
Roigas J; Deger S; Schroeder J; Wille A; Turk I; Brux B; Jung K; Schnorr D; Loening SA
Urol Res; 2003 Dec; 31(6):358-62. PubMed ID: 14513300
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
[TBL] [Abstract][Full Text] [Related]
14. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
15. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
Oremek GM; Eigenbrodt E; Rädle J; Zeuzem S; Seiffert UB
Anticancer Res; 1997; 17(4B):3031-3. PubMed ID: 9329593
[TBL] [Abstract][Full Text] [Related]
16. [Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis
and Prognosis of Stage I-II Non-small Cell Lung Cancer].
Liu Y; Wang X; Wang T; Zhang C; Zhang K; Zang R; Zhi X; Zhang W; Sun K
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):207-15. PubMed ID: 27118648
[TBL] [Abstract][Full Text] [Related]
17. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer.
Bandara IA; Baltatzis M; Sanyal S; Siriwardena AK
World J Surg Oncol; 2018 Mar; 16(1):56. PubMed ID: 29540198
[TBL] [Abstract][Full Text] [Related]
19. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.
Kumar Y; Gurusamy K; Pamecha V; Davidson BR
Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
